Loading company…
UK biotechnology company developing antiviral therapies for respiratory syncytial virus (RSV), acquired by Pfizer in 2022.
Founded in 2011 in the UK, ReViral Ltd. develops antiviral therapeutics, with a focus on respiratory syncytial virus (RSV). In April 2022, Pfizer Inc. agreed to acquire the company for approximately USD 525 mn to advance the clinical development of its RSV therapy. ReViral reported 2022 revenue of USD 7,596,122.70.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in